AKBAAkebia Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Akebia Therapeutics, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AKBAThis | $242M#8 | — | 9.7x#11 | 1.0x#3 | 47.5%#4 | 92.4%#3 | 9.9%#3 | -21.2%#6 | — | — | -68.8%#14 | — |
| TRDA | $267M#1 | — | 1.1x#3 | 10.5x#7 | -87.9%#11 | -319.0%#16 | -621.1%#8 | -61.6%#8 | — | — | 34.6%#7 | — |
| BCYC | — | — | — | — | 105.8%#3 | -29.5%#12 | -340.4%#7 | -42.9%#7 | -794.1%#2 | — | — | — |
| LYEL | $260M#2 | — | 1.1x#2 | 7229.0x#11 | -41.0%#9 | 20.0%#6 | -748344.4%#12 | -117.4%#11 | — | — | — | — |
| CAMP | $259M#3 | — | — | 73.9x#9 | 436.5%#2 | -55.2%#13 | -1502.4%#9 | — | — | — | 58.8%#5 | — |
| GLSI | $258M#4 | — | 82.9x#12 | — | — | -11.2%#9 | — | -621.1%#13 | — | — | 55.7%#6 | — |
| MGNX | $258M#5 | — | 6.0x#9 | 1.7x#4 | -0.3%#7 | -11.4%#10 | -48.7%#5 | -0.2%#4 | — | — | 162.7%#1 | — |
| FHTX | $248M#6 | — | — | 8.0x#6 | 36.8%#5 | 14.2%#8 | -279.5%#6 | — | — | — | -14.2%#10 | — |
| RNAC | $242M#7 | — | — | 606.2x#10 | -99.0%#12 | -68.3%#15 | -35851.3%#11 | — | — | — | -12.7%#9 | — |
| ALXO | $241M#9 | — | 1.8x#8 | — | — | 24.6%#5 | — | -74.7%#9 | -84.4%#1 | — | 64.6%#4 | — |
| WHWK | $232M#10 | — | 1.3x#4 | 32.5x#8 | -72.5%#10 | 67.7%#4 | -1601.1%#10 | -11.3%#5 | — | — | 107.9%#3 | — |
| NATR | $232M#11 | 13.2x#1 | 1.7x#7 | 0.5x#1 | 5.7%#6 | 153.7%#1 | 5.2%#4 | 14.3%#2 | — | 9#1 | -19.9%#11 | — |
| ZNTL | $225M#12 | — | 1.6x#6 | — | -100.0%#13 | 17.4%#7 | — | -95.4%#10 | — | — | 120.8%#2 | — |
| SIGA | $220M#13 | — | 1.3x#5 | 2.3x#5 | -31.8%#8 | -60.7%#14 | 25.1%#2 | 14.1%#3 | — | — | -57.8%#13 | 19.6%#1 |
| KROS | $219M#14 | — | 0.8x#1 | 0.9x#2 | 6775.0%#1 | 146.4%#2 | 27.7%#1 | 33.2%#1 | — | — | -29.1%#12 | — |
| ELDN | $214M#15 | — | 6.5x#10 | — | — | -26.1%#11 | — | -138.2%#12 | — | — | 8.4%#8 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice